Genome & Company (KOSDAQ:314130)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,560.00
-200.00 (-5.32%)
At close: Jul 6, 2026

Genome & Company Revenue

Genome & Company had revenue of 5.78B KRW in the quarter ending March 31, 2026, a decrease of -8.99%. This brings the company's revenue in the last twelve months to 24.02B, down -19.51% year-over-year. In the year 2025, Genome & Company had annual revenue of 24.59B, down -11.38%.

Revenue (ttm)
24.02B
Revenue Growth
-19.51%
P/S Ratio
7.08
Revenue / Employee
n/a
Employees
n/a
Market Cap
170.10B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202524.59B-3.16B-11.38%
Dec 31, 202427.74B13.45B94.07%
Dec 31, 202314.30B211.39M1.50%
Dec 31, 202214.08B13.63B3,021.27%
Dec 31, 2021451.25M300.66M199.67%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
ISU Abxis58.94B
NIBEC32.34B
Prestige Biologics18.03B
Bio Solution15.82B
TiumBio13.13B
Kangstem Biotech3.42B
Y-Biologics2.79B
curacle co.,ltd.1.06B
Revenue Rankings